ChemGenex acquires leukaemia drug outright
Wednesday, 11 June, 2008
ChemGenex (ASX: CXS) has bought the rights to the drug omacetaxine the drug omacetaxine mepesuccinate outright from Stragen Pharma, meaning the company can now sell the drug directly in Europe.
The deal negates the need for ChemGenex to offer royalty payments on sales of the drug, which was developed partly using Stragen intellectual property.
Stragen will acquire over 37 million ChemGenex shares as payment.
Omacetaxine is a treatment for patients with chronic myeloid leukaemia with the T315I mutation.
There is currently no commercially available treatment for this form of leukaemia, but ChemGenex is about to wrap up its phase II/III trial of omacetaxine.
AusBiotech partners with Tenmile
Designed to support Australia's homegrown life sciences innovation, AusBiotech has announced...
Australian CDC issues update in wake of Ebola outbreak
After the WHO determined the outbreak of Ebola in the DRC and Uganda to be a public health...
Australia announces $7.2m diphtheria outbreak response package
To respond to the biggest diphtheria outbreak on record, support has been announced for the NT...
